



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In re Application of:**

Rea et al.

**Serial No.:** 09/666,430

**Filed:** September 21, 2000

**For:** DENDRITIC CELL ACTIVATED IN  
THE PRESENCE OF GLUCOCORTICOID  
HORMONES ARE CAPABLE OF  
SUPPRESSING ANTIGEN-SPECIFIC T  
CELL RESPONSES

**Confirmation No.:** 6289

**Examiner:** G. Ewoldt

**Group Art Unit:** 1644

**Attorney Docket No.:** 3157-4205.1US

**NOTICE OF EXPRESS MAILING**

Express Mail Mailing Label Number: EV994850516US

Date of Deposit with USPS: April 27, 2005

Person making Deposit: Steve Wong

**CORRECTED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

As requested by the Examiner, the references on Form PTO/SB/08 have been corrected (1-5, and 12). Two new references are listed on this Supplemental Information Disclosure Statement (A, B and C). It is again respectfully requested that the Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).



Serial No.: 09/666,430

Other Documents

AHFS DRUG INFORMATION 91 1810 (American Society of Hospital Pharmacists, Inc., 1991).

MOLECULAR BIOLOGY OF THE CELL 1044-48 (Garland Publishing, 1989).

REMINGTON'S PHARMACEUTICAL SCIENCES 958-72 (Mack Publishing Company, Alfonso R. Gennaro ed., 1985).

*Fujikawa v. Wattanasin*, 93 F.3d. 1559, (Fed. Cir., 1996).

DICTIONARY OF GENETICS 14, 332 (Oxford University Press, 1997).

TAN, Glucocorticoids -- Disease Mechanism II: Inflammation (last modified 5-7-03)  
<<http://cgi.stanford.edu/group/hopes/cgi-bin/pfriend.pl?pathname=/group/hopes/treatmnts/antinflm/i3.html>>.

CELLULAR AND MOLECULAR IMMUNOLOGY 115-37 (W.B. Saunders Company, 1991).

HUMAN PHYSIOLOGY THE MECHANISMS OF BODY FUNCTION 599-640 (McGraw-Hill, Inc., 4th Ed. 1985).

*In re Donaldson Company, Inc.*, 29 U.S.P.Q.2d 1845 (Fed. Cir., 1994).

This Supplemental Information Disclosure Statement is believed to be filed before the mailing date of the first Office Action on the merits subsequent to the filing of an RCE in the above-identified application.

Respectfully submitted,

G. Scott Dorland, Ph.D.

Registration No. 51,622

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: April 27, 2005

GSD/bv

Enclosures: Form PTO/SB/08

Copy of documents listed as A, B and C



PTO/SB/08B(10-03)

Approved for use through 7/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	09/666,430
Filing Date	September 21, 2000
First Named Inventor	Rea et al.
Group Art Unit	1644
Examiner Name	G. Ewoldt
Attorney Docket Number	3157-4205 IUS

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	AHFS DRUG INFORMATION 91 1810 (American Society of Hospital Pharmacists, Inc., 1991).	
	2	MOLECULAR BIOLOGY OF THE CELL 1044-48 (Garland Publishing, 1989).	
	3	REMINGTON'S PHARMACEUTICAL SCIENCES 958-72 (Mack Publishing Company, Alfonso R. Gennaro ed., 1985).	
	4	<i>Fujikawa v. Wattanasin</i> , 93 F.3d. 1559, (Fed. Cir., 1996).	
	5	DICTIONARY OF GENETICS 14, 332 (Oxford University Press, 1997).	
	12	TAN, Glucocorticoids -- Disease Mechanism II: Inflammation (last modified 5-7-03) < <a href="http://cgi.stanford.edu/group/hopes/cgi-bin/pfriend.pl?pathname=/group/hopes/treatmts/antinflm/i3.html">http://cgi.stanford.edu/group/hopes/cgi-bin/pfriend.pl?pathname=/group/hopes/treatmts/antinflm/i3.html</a> >.	
	A	CELLULAR AND MOLECULAR IMMUNOLOGY 115-37 (W.B. Saunders Company, 1991).	
	B	HUMAN PHYSIOLOGY THE MECHANISMS OF BODY FUNCTION 599-640 (McGraw-Hill, Inc., 4th Ed. 1985).	
	C	<i>In re Donaldson Company, Inc.</i> , 29 U.S.P.Q.2d 1845 (Fed. Cir., 1994).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.